Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli ...
After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes ...
Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company ...
The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat ...
The trial clearance for Shanghai-based Unixell is another step forward for the rapidly advancing Chinese biotech ecosystem, ...
Xenon shares skyrocketed nearly 50% on results that handily beat Wall Street expectations. Elsewhere, Capricor got a decision date for a spurned cell therapy and AbbVie and Regeneron showcased obesity ...
The ruling, related to a lawsuit from several major medical organizations, stated that HHS ignored established protocols in altering the childhood immunization schedule and overhauling a key CDC panel ...
More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results